These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 29956210)

  • 21. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
    Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
    Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.
    Nistal E; Sáenz de Miera LE; Ballesteros Pomar M; Sánchez-Campos S; García-Mediavilla MV; Álvarez-Cuenllas B; Linares P; Olcoz JL; Arias-Loste MT; García-Lobo JM; Crespo J; González-Gallego J; Jorquera Plaza F
    Rev Esp Enferm Dig; 2019 Apr; 111(4):275-282. PubMed ID: 30810328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome.
    Quigley EM; Abu-Shanab A; Murphy EF; Stanton C; Monsour HP
    Semin Liver Dis; 2016 Sep; 36(4):312-316. PubMed ID: 27997970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study.
    Pataky Z; Genton L; Spahr L; Lazarevic V; Terraz S; Gaïa N; Rubbia-Brandt L; Golay A; Schrenzel J; Pichard C
    Dig Dis Sci; 2016 Sep; 61(9):2721-31. PubMed ID: 27142672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbial metabolites in obesity, NAFLD and T2DM.
    Canfora EE; Meex RCR; Venema K; Blaak EE
    Nat Rev Endocrinol; 2019 May; 15(5):261-273. PubMed ID: 30670819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
    Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
    Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
    Jayachandran M; Qu S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.
    Doulberis M; Kotronis G; Gialamprinou D; Kountouras J; Katsinelos P
    Metabolism; 2017 Jun; 71():182-197. PubMed ID: 28521872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease.
    Shama S; Liu W
    Dig Dis Sci; 2020 Mar; 65(3):906-910. PubMed ID: 32036510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids.
    Janssen AWF; Houben T; Katiraei S; Dijk W; Boutens L; van der Bolt N; Wang Z; Brown JM; Hazen SL; Mandard S; Shiri-Sverdlov R; Kuipers F; Willems van Dijk K; Vervoort J; Stienstra R; Hooiveld GJEJ; Kersten S
    J Lipid Res; 2017 Jul; 58(7):1399-1416. PubMed ID: 28533304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
    Ji Y; Yin Y; Li Z; Zhang W
    Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
    Yang YJ; Ni YH
    J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.